Hanyu Pharmaceutical and KuCoin Reach Strategic Cooperation to Promote Innovative Drug RWA Project

According to reports from Hash Chain, Hanyu Pharmaceutical signed a strategic cooperation agreement with the digital asset platform KuCoin on August 4. Both parties plan to launch a pilot project for tokenization of RWA with 'future revenue rights of innovative drug R&D' as the underlying asset in Hong Kong. According to the agreement, Hanyu Pharmaceutical will base its assets on its technological accumulation and R&D pipeline in the field of GLP-1 class peptide blockbuster drugs, while KuCoin will leverage its advantages in blockchain technology, RWA process solutions, and global compliance resources to provide comprehensive support for the project, including on-chain reflection, asset tokenization, transaction matching, and revenue distribution.